Radiotherapy Improves Local Control of Advanced Sinus Cancer

M. Alexander Otto, PA, MMS

July 15, 2022

The study was published on researchsquare.com as a preprint and has not yet been peer reviewed.

Key Takeaway

  • By allowing higher radiation doses, intensity-modulated radiotherapy (IMRT) alongside intra-arterial cisplatin, substantially improves local control in advanced maxillary sinus cancer without an increase in adverse events compared with 3-dimensional conformal radiotherapy (3DCRT).

Why This Matters

  • Superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy (RADPLAT) is an alternative to potentially disfiguring surgery. 

  • IMRT vs 3DCRT allows for higher radiation doses to the tumor while decreasing exposure to healthy tissue.  

  • The study may be the first to report the relationship between total radiation dose and treatment outcomes.

Study Design

  • Investigators reviewed 58 patients with localized maxillary sinus cancer treated with RADPLAT from 2004 to 2020.

  • Radiation was delivered by 3DCRT in 34 patients and IMRT in 24.

Key Results

  • The median prescribed dose to the local lesion was 66 Gy in the 3DCRT group and 70 Gy in the IMRT group.

  • Patients who were treated with 70 Gy using IMRT had a significantly higher local control rate (87.7%) than patients treated with 66 Gy (72.1%) or 60 Gy or below (41%).

  • The 5-year overall survival rate was 88.5% for those in 70 Gy group, 66.6% in the 66 Gy group, and 72.7% in the 60 Gy or less group.

  • One patient had grade 3 or higher eye disorder (cataracts) in the IMRT group; the authors observed four cases of blindness in the 3DCRT group.

Limitations

  • No study limitations were reported.

Disclosures

  • There was no funding for the work, and the investigators did not report any disclosures.

This is a summary of a preprint research study, "Impact of total radiation dose on treatment outcomes of radiotherapy and concomitant superselective intra-arterial high-dose cisplatin in localized maxillary sinus cancer," led by Kenta Konishi of the Hamamatsu University School of Medicine, Japan. The study has not been peer reviewed. The full text can be found at researchsquare.com.

M. Alexander Otto is a physician assistant with a master’s degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who has worked for several major news outlets before joining Medscape and also an MIT Knight Science Journalism fellow. Email: aotto@mdedge.com.

For more news, follow Medscape on  Facebook,   Twitter,   Instagram, and  YouTube.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....